HOME >> MEDICINE >> NEWS
International study highlights underuse of reperfusion therapy for heart-attack patients

N.B. Please note that if you are outside North America the embargo time for Lancet Press Material is 0001 hours UK Time Friday 1st February 2002.

Up to a third of patients with a severe heart attack may not be receiving reperfusion therapy, despite the well-known benefits of this treatment strategy, conclude authors of an international study in this weeks issue of THE LANCET.

The benefits of reperfusion therapy- the use of fibrinolytic agents and/or coronary angioplasty to restore coronary artery bloodflow -for patients with acute coronary syndromes have been established, but there is variation in the type of reperfusion given and in decisions about which patients are eligible for such therapy. Kim Eagle from the University of Michigan Medical Center, USA, and colleagues assessed current practices in relation to reperfusion therapy in patients with a specific heart-attack profile called ST-segment-elevation myocardial infarction using data from the multinational, prospective Global Registry of Acute Coronary Events (GRACE). This registry includes data for patients with acute coronary syndromes from 94 hospitals in 14 countries.

The investigators assessed data of the first 9251 patients enrolled in GRACE; of these, 1763 presented within 12 hours of symptom onset with ST-segment-elevation myocardial infarction, 30% of whom did not receive reperfusion therapy. Elderly patients (75 years and older), those presenting without chest pain, and those with a history of diabetes, congestive heart failure, myocardial infarction, or coronary bypass surgery were less likely to receive reperfusion therapy. The rate of primary percutaneous coronary intervention was highest in the USA (17%) and lowest in Australia, New Zealand, and Canada (1%). The rate at sites with a catheterisation laboratory was 19%.

Kim Eagle comments: A substantial proportion of patients who are eligible for reperfusion therapy still do not receive this treatment.
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7611-4076
Lancet
31-Jan-2002


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. National Academies advisory: May 2 Symposium on International Science Policy
3. Awards & fellowships at the International & American Association for Dental Research General Session
4. Lectures, keynoters, symposia highlight International Dental Research meeting
5. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
6. International gathering of experts to share retinoblastoma breakthroughs
7. International trial of two microbicides begins
8. International gathering at UH examines top computer code
9. International trial finds benefits of breast MRI in women at high risk
10. International study provides culture-by-culture clues to family violence and abuse
11. St. Jude scientist wins International Society of Experimental Hematology award

Post Your Comments:
(Date:7/25/2014)... The Europe Cyber Security report defines and segments ... and forecast of revenue. This market is estimated to ... billion by 2019, at a CAGR of 7.10% from ... the Europe Cyber Security Market report to get an ... a glimpse of the segmentation in this market, and ...
(Date:7/25/2014)... Amherst, NH (PRWEB) July 25, 2014 ... Dubois has joined the company as a Creative Enrollment ... his extensive relationship building skills as well as his ... portfolio of small business clients, and to service the ... . Additionally, Greg will work with small business ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) ... Trainer of Distinguished Events, and Corporate and Special Events ... Society, will be joining the ABTA in the newly ... oversee the roll out of a nationwide brain tumor ... recently launched volunteer network will provide the Chicago-based ABTA ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) today ... during its annual patient and family conference in Chicago. ... tumor community as we – the first and now ... and funding brain tumor research – extend our reach ... awareness and getting our materials and services into the ...
(Date:7/25/2014)... “You have a brain tumor.” These five ... their loved ones across the U.S. every day. According to ... is typically met with confusion and uncertainty as families struggle ... and make critical decisions about a course of treatment. The ... by a sense of isolation and a frantic and, far ...
Breaking Medicine News(10 mins):Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
Cached News: